CD81 Monoclonal Antibody (M38), Invitrogen™

Description

• Positive control: Jurkat cells, non-reducing conditions
• Functional application: In human MOLT-4 T-cell line the antibody M38 inhibits syncytium formation induced by coculture with human T-cell leukemia virus type 1 (HTLV-1)-positive human T-cell lines
• CD81 (TAPA-1, target of anti-proliferative antibody-1) is a member of the tetraspanin family, is expressed on virtually all nucleated cells, but above all on germinal center B cells
• CD81 forms complexes with other tetraspanin proteins, integrins, coreceptors, MHC class I and II molecules, and influences adhesion, morphology, activation, proliferation and differentiation of B, T cells
• In muscles, CD81 promotes cell fusion and myotube maintenance
• CD81 has been also identified as a receptor for the hepatitis C virus
• Like members of the tetraspanin family that include CD9, CD37, CD53, CD63, and CD82, CD81 is a cell-surface proteins that are characterized by the presence of four hydrophobic domains
• The proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth and motility
• CD81 is a cell surface glycoprotein that is known to complex with integrins
• CD81 appears to promote muscle cell fusion and support myotube maintenance
• CD81 associates with CD19, CD21, Leu 13, and integrins on cell membrane and acts as a receptor for the envelope protein E2 of chronic hepatitis C virus
• Antibodies to CD81 have anti-proliferative effects on different lymphoid cell lines, particularly those derived from large cell lymphomas
• CD81 is also localized in the tumor-suppressor gene region and is a candidate gene for malignancies.